Geron gets 50% enrollment in IMpactMF trial for Imetelstat in MF patients

Geron announced achievement of fifty percent enrollment in the Phase 3 IMpactMF clinical trial investigating the Company’s first-in-class telomerase inhibitor, imetelstat, versus best available therapy BAT in patients with relapsed/refractory myelofibrosis or MF. “Reaching fifty percent enrollment in IMpactMF is an important milestone towards the completion of this first-of-its-kind registration-enabling trial, and we are very grateful to all of the investigators, research staff and patients who are participating,” said Faye Feller, M.D., Executive Vice President, Geron’s Chief Medical Officer. “This is the first Phase 3 trial to evaluate overall survival as a primary endpoint in relapsed/refractory MF and is also the first Phase 3 trial investigating a telomerase inhibitor in this patient population. We believe that if IMpactMF confirms the clinical benefits of symptom response and overall survival observed in the Phase 2 IMbark study, that imetelstat could become a standard of care in relapsed/refractory myelofibrosis.” An interim analysis is expected when ~35% of the planned enrolled patients have died and a final analysis is expected when more than 50% of the planned enrolled patients have died. Based on projected planning assumptions for enrollment and death rates in the trial, interim analysis is expected in the first half of 2025 and final analysis is expected in the first half of 2026.